证券代码：002173 证券简称：创新医疗 公告编号：2025-016 创新医疗管理股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 审议程序 1 / 2 基于公司 2024 年度净利润为负数，尚不具备现金分红能力，同时综合考虑 行业现状、战略规划和未来资金需求等因素，为保障公司持续、稳定、健康发展， 更好地维护全体股东的长远利益，2024 年度公司拟不进行利润分配，也不以公 积金转增股本。 二、2024 年度利润分配预案的基本情况 （一）2024 年度利润情况以及 2024 年末可供分配利润情况 2024 年度，公司实现归属于上市公司股东的净利润-9,395.40 万元，合并报 表可供分配利润-139,819.17 万元。母公司实现净利润 4,983.30 万元，母公司 报表可供分配利润-109,910.91 万元。 因公司、母公司 2024 年末可供分配利润为负，不具备实施现金分红的条件。 基于上述情况，公司董事会提出 2024 年度利润分配预案为：2024 年度拟不进行 利润分配，也不以公积金转增 ...

Financial Performance - The company's operating revenue for 2024 was ¥816,018,808.41, representing a 1.30% increase from ¥805,585,526.56 in 2023[18]. - The net profit attributable to shareholders for 2024 was -¥93,954,030.31, a decrease of 174.02% compared to -¥34,287,743.35 in 2023[18]. - The net cash flow from operating activities was -¥7,344,279.65 in 2024, a decline of 166.58% from ¥11,030,985.78 in 2023[18]. - The basic earnings per share for 2024 was -¥0.21, down 162.50% from -¥0.08 in 2023[18]. - Total assets at the end of 2024 were ¥2,203,947,708.41, a decrease of 3.40% from ¥2,281,472,772.53 at the end of 2023[18]. - The net assets attributable to shareholders decreased by 5.02% to ¥1,776,198,085.17 at the end of 2024 from ¥1,870,152,115.48 at the end of 2023[18]. - The company reported a total of ¥287.80 million in trading financial assets at the end of the period, a 12.18% increase from the beginning of the year[57]. - The company’s long-term equity investments increased from ¥15.22 million at the beginning of the year to ¥41.75 million at the end of the period, reflecting a 1.22% increase in total assets[57]. - The company’s total distributable profit is reported as -¥1,398,191,741.89, indicating a negative balance[116]. Revenue Sources - The company reported a significant increase in other business income, which rose to ¥3,878,450.29 in 2024 from ¥1,694,468.81 in 2023[19]. - The medical service business accounted for 99.52% of total revenue, with a revenue of CNY 812.14 million, up 1.03% year-on-year[41]. - The company’s gross profit margin for medical services was 7.54%, a decrease of 3.78% compared to the previous year[44]. - The company’s operating costs for medical services were CNY 750.87 million, an increase of 5.33% from CNY 712.90 million in 2023[46]. Operational Challenges - The company has indicated potential risks in its future operations, which investors should be aware of[4]. - The company reported a decrease in gross profit margin due to dynamic adjustments in medical insurance payment standards[28]. - The net profit attributable to shareholders was -66.11 million yuan in Q4, with a total of -66.05 million yuan for the year, indicating significant losses[23]. - The net cash flow from operating activities was -22.98 million yuan in Q4, highlighting cash flow challenges[23]. - The company faces risks from policy changes in the healthcare industry, increasing competition, and the need for skilled personnel[69][70]. Strategic Initiatives - The company has undergone a strategic transformation to focus primarily on providing high-quality medical services[17]. - The company is focusing on enhancing service quality and operational capabilities through strategic partnerships with renowned medical institutions[33]. - The company plans to continue integrating supply chain management to reduce costs and improve efficiency[30]. - The company plans to enhance hospital operational capabilities and efficiency while focusing on innovation and the integration of emerging medical technologies, including AI[68]. - The company is actively expanding its market presence by collaborating with leading medical institutions to enhance resource sharing and improve diagnostic capabilities[38]. Shareholder and Governance - The company has maintained a governance structure that complies with relevant laws and regulations, holding 9 board meetings and 4 supervisory meetings during the reporting period[81]. - The company operates independently from its controlling shareholder in all aspects, including business, personnel, assets, and finance[83]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[81]. - The company has established a dedicated financial department with an independent accounting system and financial management practices[85]. - The company has successfully engaged with investors through various communication channels, ensuring transparency and information disclosure[82]. Employee Management - The company reported a total of 2,673 employees at the end of the reporting period, with 1,000 nurses and 662 doctors among them[112]. - The employee compensation structure includes basic salary, position allowances, and attendance bonuses, with annual adjustments based on industry conditions and company performance[113]. - The company implements a training plan combining internal and external training for medical staff to enhance service quality and communication skills[114]. - The company is committed to maintaining a performance-based compensation system to motivate employees effectively[113]. Compliance and Internal Control - The internal control system has been continuously improved to enhance risk prevention and support high-quality development[119]. - There were no significant internal control deficiencies identified during the reporting period[122]. - The company received a standard unqualified opinion on its internal control audit report, indicating no significant deficiencies in non-financial reporting[124]. - The company has completed rectifications for issues identified during its self-inspection of corporate governance, aiming to enhance governance standards and promote high-quality development[124]. Future Outlook - By 2025, the company aims to strengthen its hospital culture, improve quality management, and optimize clinical pathways, with a focus on high-quality development[68]. - The company has established a strategic partnership with Huawei to release the "全诊昇腾 DeepSeek model computing integration machine" in March 2025[76]. - The B-end products of the company have officially commenced multi-center clinical trials at three hospitals, with the registration application for Class II medical devices expected to be completed in the first half of 2026[73]. - The C-end product, designed for stroke patients, has entered mass production and is expected to be launched for sale in 2025[75].

此外，飞利浦星云三维影像数据中心 - 光谱云魔镜解决方案也在本次展会亮相，延续"从医生的习惯出发"的设计理念，支持访问覆盖多种主流病种的多模态 影像数据，提高临床诊断信心。同时通过统一操作界面和高效工作流程，减轻临床负担，提升工作效率。 值得一提的是，在时代浪潮下，飞利浦将可持续发展理念深度融入产品创新与服务优化的每一个环节。本次展出的BlueSeal 2.0无液氦双芯磁共振通过无液 氦磁共振技术重新定义行业标准。其自主研发的BlueSeal 2.0磁体突破传统液氦依赖，仅需传统设备0.5% 的氦气消耗量，从源头解决全球氦气短缺与失超风 险问题。截至 2024 年底，飞利浦无液氦磁共振已在全球装机超过1700台，累计节省超500 万升液氦，相当于减少 3.2 万吨二氧化碳排放。 从人工智能技术突破来看，在影像引导治疗领域，飞利浦搭载Clarity IQ的Azurion血管造影系统在中国迎来首发首展。其采用超过 500 个参数优化的高清模 型，并根据医生习惯定制图像风格，在提高图像质量的同时降低辐射剂量，让医生和患者都能从中获益。 在超声领域，飞利浦带来了EPIQ CVxi 心血管Al介入诊疗一体超声系统，采用 ...

来源：金融界 中银创新医疗混合A股票持仓前十占比合计70.60%，分别为：恒瑞医药（9.81%）、信达生物 （8.55%）、和黄医药（8.41%）、康方生物（8.35%）、康诺亚-B（8.32%）、科伦博泰生（7.87%）、 百济神州-U（6.24%）、荣昌生物（5.96%）、翰森制药（3.98%）、新诺威（3.11%）。 金融界2025年4月9日消息，中银创新医疗混合A(007718) 最新净值1.4557元，增长1.58%。该基金近1个 月收益率2.80%，同类排名22|3788；近3个月收益率27.12%，同类排名12|3756；今年来收益率20.98%， 同类排名24|3754。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 公开资料显示，中银创新医疗混合A基 ...

4月7日，创新医疗今日收盘8.49元，下跌9.97%，最新市净率2.03，总市值37.47亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)6创新医疗-78.19-109.272.0337.47亿行业平均 45.7240.943.28142.68亿行业中值41.8333.882.5543.24亿1普瑞眼科-173.2621.662.6258.02亿2何氏眼 科-136.5041.851.3726.60亿3光正眼科-86.53205.596.9719.03亿4迪安诊断-85.2825.671.1278.93亿5南华生 物-80.12-105.4311.9529.70亿7国际医学-31.81-30.933.12113.92亿8嘉和美康-25.49-25.492.1438.24亿9皓宸 医疗-21.61-22.254.6921.00亿10美迪西-11.36-11.361.5335.89亿11和元生物-10.03-10.031.7432.58亿 来源：金融界 创新医疗管理股份有限公司是一家以提供医疗服务为主营业务的上市公司,公司下属有建华医院、康华 医院、福恬医院和明珠医院四家医疗机构，建华医院是三级甲等 ...

在国家深化医保改革、构建"基本医保+商业健康保险"多层次保障体系的背景下，居民对高品质医疗服 务和多元化健康保障的需求日益凸显。为响应《"健康中国2030"规划纲要》及保险业新"国十条"号召， 大家人寿近日推出创新医疗险产品"大家臻守护医疗保险"，以住院医疗费用补偿为主要保障内容， 以"创新医疗保障+品质服务"为核心，助力缓解"看病贵、优质医疗资源不可及"的社会痛点，彰显商业 健康险的社会价值。 近年来，随着我国医保体系从"广覆盖"向"高质量"转型，商业健康险的补充作用日益凸显。大家臻守护 医疗保险通过三大创新设计精准对接政策导向。 一是突破医疗资源壁垒。覆盖公立医院特需部、国际部及优质私立医院，打破传统医疗险仅限公立医院 普通部的局限，以亲民价格享受优质医疗资源，缓解公立医院特需服务"供需错配"难题。 三大创新设计，臻守护实现真守护 二是填补新技术保障缺口。将新型疗法、创新药品及先进器械费用纳入保障范围，解决重大疾病患者因 医疗技术迭代产生的自费负担，助力国家"鼓励医疗创新"政策落地。 三是强化适老化金融服务。首次投保年龄放宽至65周岁，续保可至100周岁，为老年群体提供长期稳定 的医疗保障，适配老龄化社会 ...

上海康瀚投资管理中心（有限合伙）（以下简称"康瀚投资"）作为齐齐哈尔建华医院有限责任公司（以 下简称"建华医院"）的业绩承诺人，迄今为止并未履行业绩补偿义务。因此，康瀚投资所持创新医疗管 理股份有限公司（以下简称"公司"）股份在锁定期满后，继续保持限售状态。韩猛于2024年12月11日通 过司法执行过户的方式，取得原由康瀚投资持有的450万股处于限售状态的公司股份。近日，公司收到 上海市浦东新区人民法院《民事起诉状》等，韩猛以公司未办理相关股份的解除限售手续为案由起诉公 司及公司董事。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002173 证券简称：创新医疗 公告编号：2025-011 创新医疗管理股份有限公司 关于诉讼事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本次诉讼的基本情况 二、有关本次诉讼的基本情况 （一）诉讼各方当事人 原告：韩猛 被告一：创新医疗管理股份有限公司 《民事起诉状》陈述的相关内容如下： "1、请求依法判令各被告停止对原告股东权利的侵害，立即为原告所持的全部4,500,000股"创新医 疗"（证券 ...

截至2025年3月28日收盘，创新医疗（002173）报收于9.14元，较上周的11.83元下跌22.74%。本周，创 新医疗3月24日盘中最高价报10.95元。3月28日盘中最低价报9.14元。本周无涨停收盘情况，共计1次跌 停收盘。创新医疗当前最新总市值41.61亿元，在医疗服务板块市值排名33/50，在两市A股市值排名 3322/5140。 本周关注点 建华医院公司就与江苏齐丰重工有限公司、齐齐哈尔建华医院、韩雪梅、韩飞、张丽、龙泯的侵权责任 纠纷，向广东省深圳市宝安区人民法院提起诉讼，并收到《受理案件通知书》。建华医院公司请求依法 判决齐丰重工、民非建华、韩雪梅赔偿财产损失26,463,966.82元；韩飞返还2,700,000.00元及自2017年4 月17日起按月利率1%计算至实际履行之日的利息；张丽返还2,300,000.00元及相应利息；龙泯返还 3,000,000.00元及相应利息；并要求各被告承担律师费、保全费、诉讼费等费用。建华医院公司在已足 额支付工程款的情况下，被法院判决需再支付工程款15,090,000.00元及逾期付款利息7,132,478.08元，最 终被强制执行26,463, ...

公开资料显示，中银创新医疗混合A基金成立于2019年11月13日，截至2024年12月31日，中银创新医疗 混合A规模20.20亿元，基金经理为郑宁。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 来源：金融界 金融界2025年4月3日消息，中银创新医疗混合A(007718) 最新净值1.6253元，下跌0.58%。该基金近1个 月收益率17.65%，同类排名3|2064；近3个月收益率38.89%，同类排名14|2055；今年来收益率35.07%， 同类排名14|2055。 中银创新医疗混合A股票持仓前十占比合计70.60%，分别为：恒瑞医药（9.81%）、信达生物 （8.55%）、和黄医药（8.41%）、康方生物（8.35%）、康诺亚-B（8.32%）、科伦博泰生 ...

Group 1 - The lawsuit involves Shanghai Kanghan Investment Management Center (Limited Partnership) as the performance guarantor for Qiqihar Jianhua Hospital, which has not fulfilled its performance compensation obligations, resulting in the continued lock-up status of shares held by Kanghan Investment in Innovation Medical Management Co., Ltd [1][2] - The plaintiff, Han Meng, has filed a lawsuit against the company and its board members, requesting the immediate lifting of the lock-up on 4,500,000 shares, with a claimed value of RMB 30,415,500 [1][3] - The lawsuit claims that the company has failed to fulfill its legal obligation to process the lifting of the lock-up on the shares, which has caused significant economic losses to the plaintiff [3] Group 2 - The shares in question were issued as part of a non-public offering to Kanghan Investment for the acquisition of 100% equity in Jianhua Hospital, with a lock-up period of 36 months [2] - The company and its board have not acted on multiple communications from the plaintiff regarding the lifting of the lock-up, which is seen as a violation of shareholder rights [3] - The company plans to hire legal counsel to actively respond to the lawsuit and will monitor the case's progress while fulfilling its disclosure obligations [3]